Sangamo Therapeutics (SGMO) to Release Quarterly Earnings on Thursday

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Sangamo Therapeutics to post earnings of ($0.12) per share and revenue of $7.90 million for the quarter.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The firm had revenue of $7.55 million during the quarter, compared to analysts' expectations of $11.70 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. On average, analysts expect Sangamo Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sangamo Therapeutics Stock Performance

NASDAQ SGMO traded down $0.01 during trading hours on Friday, reaching $0.73. The stock had a trading volume of 1,932,647 shares, compared to its average volume of 8,586,445. Sangamo Therapeutics has a 52-week low of $0.30 and a 52-week high of $3.18. The stock has a fifty day moving average of $0.81 and a 200 day moving average of $1.38. The stock has a market cap of $166.92 million, a P/E ratio of -0.97 and a beta of 1.46.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on SGMO. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Royal Bank of Canada reiterated a "sector perform" rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Finally, Truist Financial decreased their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $5.17.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.